Table 1.
Characteristics of the study patients
| Characteristics | All patients (n = 145) |
|---|---|
| eGFR slope (ml/min per 1.73 m2 per year) | −0.57 ± 3.32 |
| Age (years) | 68.6 ± 12.1 |
| Male gender (%) | 68.3 |
| Smoking history (%) | 56.3 |
| Diabetes mellitus (%) | 49.7 |
| Hypertension (%) | 84.1 |
| Coronary artery disease (%) | 18.6 |
| Cerebrovascular disease (%) | 19.3 |
| Stage of CKD | |
| stage 3 (%) | 52.4 |
| stage 4 (%) | 28.3 |
| stage 5 (%) | 19.3 |
| Systolic BP (mmHg) | 142.4 ± 21.2 |
| Diastolic BP (mmHg) | 78.9 ± 11.5 |
| Pulse pressure (mmHg) | 64.1 ± 16.9 |
| Heart rate (beats/min) | 74.0 ± 13.7 |
| Body mass index (kg/m2) | 25.9 ± 4.8 |
| Laboratory parameters | |
| albumin (g/dl) | 3.99 ± 0.34 |
| fasting glucose (mg/dl) | 121.4 ± 45.8 |
| triglyceride (mg/dl) | 166.4 ± 98.9 |
| total cholesterol (mg/dl) | 196.9 ± 44.3 |
| HDL-cholesterol (mg/dl) | 45.7 ± 13.4 |
| LDL-cholesterol (mg/dl) | 112.1 ± 33.4 |
| hematocrit (%) | 36.6 ± 6.6 |
| basline eGFR (ml/min per 1.73 m2) | 29.9 ± 14.7 |
| calcium (mg/dl) | 9.6 ± 0.7 |
| phosphate (mg/dl) | 3.8 ± 0.8 |
| uric acid (mg/dl) | 8.3 ± 2.3 |
| PTH (pg/ml) | 65.4 ± 101.5 |
| Albuminuria (%) | 73.2 |
| baPWVa (cm/s) | 2055.3 ± 920.5 |
| Medications | |
| aspirin use (%) | 28.3 |
| ACEI and/or ARB use (%) | 78.5 |
| β-blocker use (%) | 24.5 |
| calcium channel blocker use (%) | 57.2 |
| diuretic use (%) | 40.0 |
| statin use (%) | 27.3 |
| ESA use (%) | 7.6 |
eGFR, estimated glomerular filtration rate; CKD, chronic kidney disease; HDL, high-density lipoprotein; LDL, low-density lipoprotein; PTH, parathyroid hormone; baPWV, brachial-ankle pulse wave velocity; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker; ESA, erythropoiesis stimulating agent.
a
Data were adjusted for mean arterial pressure.